132 related articles for article (PubMed ID: 26961318)
1. Sirtuin Inhibitors: An Overview from Medicinal Chemistry Perspective.
Yoon YK; Oon CE
Anticancer Agents Med Chem; 2016; 16(8):1003-1016. PubMed ID: 26961318
[TBL] [Abstract][Full Text] [Related]
2. Inhibitors of NAD+ dependent histone deacetylases (sirtuins).
Neugebauer RC; Sippl W; Jung M
Curr Pharm Des; 2008; 14(6):562-73. PubMed ID: 18336301
[TBL] [Abstract][Full Text] [Related]
3. Inhibitors to understand molecular mechanisms of NAD(+)-dependent deacetylases (sirtuins).
Lawson M; Uciechowska U; Schemies J; Rumpf T; Jung M; Sippl W
Biochim Biophys Acta; 2010; 1799(10-12):726-39. PubMed ID: 20601279
[TBL] [Abstract][Full Text] [Related]
4. Targeting Sirtuins: Substrate Specificity and Inhibitor Design.
Rajabi N; Galleano I; Madsen AS; Olsen CA
Prog Mol Biol Transl Sci; 2018; 154():25-69. PubMed ID: 29413177
[TBL] [Abstract][Full Text] [Related]
5. NAD(+) -dependent histone deacetylases (sirtuins) as novel therapeutic targets.
Schemies J; Uciechowska U; Sippl W; Jung M
Med Res Rev; 2010 Nov; 30(6):861-89. PubMed ID: 19824050
[TBL] [Abstract][Full Text] [Related]
6. Medicinal chemistry of sirtuin inhibitors.
Chen L
Curr Med Chem; 2011; 18(13):1936-46. PubMed ID: 21517778
[TBL] [Abstract][Full Text] [Related]
7. Sirtuin-targeting drugs: Mechanisms of action and potential therapeutic applications.
Aljada A; Dong L; Mousa SA
Curr Opin Investig Drugs; 2010 Oct; 11(10):1158-68. PubMed ID: 20872319
[TBL] [Abstract][Full Text] [Related]
8. Adenosine mimetics as inhibitors of NAD+-dependent histone deacetylases, from kinase to sirtuin inhibition.
Trapp J; Jochum A; Meier R; Saunders L; Marshall B; Kunick C; Verdin E; Goekjian P; Sippl W; Jung M
J Med Chem; 2006 Dec; 49(25):7307-16. PubMed ID: 17149860
[TBL] [Abstract][Full Text] [Related]
9. Sirtuins and Their Implications in Neurodegenerative Diseases from a Drug Discovery Perspective.
Yeong KY; Berdigaliyev N; Chang Y
ACS Chem Neurosci; 2020 Dec; 11(24):4073-4091. PubMed ID: 33280374
[TBL] [Abstract][Full Text] [Related]
10. Sirtuins (histone deacetylases III) in the cellular response to DNA damage--facts and hypotheses.
Kruszewski M; Szumiel I
DNA Repair (Amst); 2005 Nov; 4(11):1306-13. PubMed ID: 16084131
[TBL] [Abstract][Full Text] [Related]
11. Sirtuins as pharmacological targets in neurodegenerative and neuropsychiatric disorders.
Leite JA; Ghirotto B; Targhetta VP; de Lima J; Câmara NOS
Br J Pharmacol; 2022 Apr; 179(8):1496-1511. PubMed ID: 34029375
[TBL] [Abstract][Full Text] [Related]
12. After the grape rush: sirtuins as epigenetic drug targets in neurodegenerative disorders.
Huber K; Superti-Furga G
Bioorg Med Chem; 2011 Jun; 19(12):3616-24. PubMed ID: 21306906
[TBL] [Abstract][Full Text] [Related]
13. NAD+-dependent deacetylation of H4 lysine 16 by class III HDACs.
Vaquero A; Sternglanz R; Reinberg D
Oncogene; 2007 Aug; 26(37):5505-20. PubMed ID: 17694090
[TBL] [Abstract][Full Text] [Related]
14. Small molecule regulation of Sir2 protein deacetylases.
Grubisha O; Smith BC; Denu JM
FEBS J; 2005 Sep; 272(18):4607-16. PubMed ID: 16156783
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone deacetylases: perspectives for epigenetic-based therapy in cardio-cerebrovascular disease.
Wang ZY; Qin W; Yi F
J Geriatr Cardiol; 2015 Mar; 12(2):153-64. PubMed ID: 25870619
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of sirtuin-activating compounds in Alzheimer's disease.
Gan L
Drug News Perspect; 2007 May; 20(4):233-9. PubMed ID: 17637936
[TBL] [Abstract][Full Text] [Related]
17. Transcription Regulation by Class III Histone Deacetylases (HDACs)-Sirtuins.
Dai Y; Faller DV
Transl Oncogenomics; 2008 Apr; 3():53-65. PubMed ID: 21566744
[TBL] [Abstract][Full Text] [Related]
18.
Dindi UMR; Sadiq SP; Al-Ghamdi S; Alrudian NA; Dayel SB; Abuderman AA; Shahid M; Ramesh T; Vilwanathan R
Front Med (Lausanne); 2023; 10():1282820. PubMed ID: 38020163
[TBL] [Abstract][Full Text] [Related]
19. The chemical biology of sirtuins.
Chen B; Zang W; Wang J; Huang Y; He Y; Yan L; Liu J; Zheng W
Chem Soc Rev; 2015 Aug; 44(15):5246-64. PubMed ID: 25955411
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic potential of activators and inhibitors of sirtuins.
Balcerczyk A; Pirola L
Biofactors; 2010; 36(5):383-93. PubMed ID: 20848588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
